170 related articles for article (PubMed ID: 38634984)
1. Genetic and Phenotypic Profiling of Triptan Users in a Swedish Cluster Headache Cohort.
Jennysdotter Olofsgård F; Ran C; Qin Y; Fourier C; Waldenlind E; Steinberg A; Sjöstrand C; Belin AC
J Mol Neurosci; 2024 Apr; 74(2):45. PubMed ID: 38634984
[TBL] [Abstract][Full Text] [Related]
2. Bi-allelic and tri-allelic 5-HTTLPR polymorphisms and triptan non-response in cluster headache.
Schürks M; Frahnow A; Diener HC; Kurth T; Rosskopf D; Grabe HJ
J Headache Pain; 2014 Jul; 15(1):46. PubMed ID: 25043824
[TBL] [Abstract][Full Text] [Related]
3. Identifying the factors underlying discontinuation of triptans.
Wells RE; Markowitz SY; Baron EP; Hentz JG; Kalidas K; Mathew PG; Halker R; Dodick DW; Schwedt TJ
Headache; 2014 Feb; 54(2):278-89. PubMed ID: 24001117
[TBL] [Abstract][Full Text] [Related]
4. Using a Genetic Risk Score Approach to Predict Headache Response to Triptans in Migraine Without Aura.
Cargnin S; Viana M; Sances G; Cantello R; Tassorelli C; Terrazzino S
J Clin Pharmacol; 2019 Feb; 59(2):288-294. PubMed ID: 30256423
[TBL] [Abstract][Full Text] [Related]
5.
Martínez-Pías E; García-Azorín D; Minguez-Olaondo A; Trigo J; Sierra Á; Ruiz M; Guerrero ÁL
Expert Rev Neurother; 2021 Jan; 21(1):123-130. PubMed ID: 33111580
[No Abstract] [Full Text] [Related]
6. Triptan education and improving knowledge for optimal migraine treatment: an observational study.
Baron EP; Markowitz SY; Lettich A; Hastriter E; Lovell B; Kalidas K; Dodick DW; Schwedt TJ;
Headache; 2014 Apr; 54(4):686-97. PubMed ID: 24520930
[TBL] [Abstract][Full Text] [Related]
7. Predictors of acute treatment response among patients with cluster headache.
Schürks M; Rosskopf D; de Jesus J; Jonjic M; Diener HC; Kurth T
Headache; 2007; 47(7):1079-84. PubMed ID: 17635600
[TBL] [Abstract][Full Text] [Related]
8. Adding Additional Acute Medications to a Triptan Regimen for Migraine and Observed Changes in Headache-Related Disability: Results From the American Migraine Prevalence and Prevention (AMPP) Study.
Buse DC; Serrano D; Reed ML; Kori SH; Cunanan CM; Adams AM; Lipton RB
Headache; 2015 Jun; 55(6):825-39. PubMed ID: 25881857
[TBL] [Abstract][Full Text] [Related]
9. Triptans for Acute Migraine Headache: Current Experience With Triptan Use and Prescription Habits in a Tertiary Care Headache Outpatient Clinic: An Observational Study.
Fischer M; Frank F; Wille G; Klien S; Lackner P; Broessner G
Headache; 2016 Jun; 56(6):952-60. PubMed ID: 27091593
[TBL] [Abstract][Full Text] [Related]
10. Triptan non-response in specialized headache care: cross-sectional data from the DMKG Headache Registry.
Ruscheweyh R; Gossrau G; Dresler T; Freilinger T; Förderreuther S; Gaul C; Kraya T; Neeb L; Ruschil V; Straube A; Scheidt J; Jürgens TP
J Headache Pain; 2023 Oct; 24(1):135. PubMed ID: 37817093
[TBL] [Abstract][Full Text] [Related]
11. Association between response to triptans and response to erenumab: real-life data.
Frattale I; Caponnetto V; Casalena A; Assetta M; Maddestra M; Marzoli F; Affaitati G; Giamberardino MA; Viola S; Gabriele A; Pistoia F; Cerone D; Marini C; Sacco S; Ornello R
J Headache Pain; 2021 Jan; 22(1):1. PubMed ID: 33407070
[TBL] [Abstract][Full Text] [Related]
12. Impact of NSAID and Triptan use on developing chronic migraine: results from the American Migraine Prevalence and Prevention (AMPP) study.
Lipton RB; Serrano D; Nicholson RA; Buse DC; Runken MC; Reed ML
Headache; 2013; 53(10):1548-63. PubMed ID: 23992516
[TBL] [Abstract][Full Text] [Related]
13. Usage of triptans among migraine patients: an audit in nine GP practices.
Williams D; Cahill T; Dowson A; Fearon H; Lipscombe S; O'Sullivan E; Rees T; Strang C; Valori A; Watson D
Curr Med Res Opin; 2002; 18(1):1-9. PubMed ID: 11999139
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of eletriptan in triptan-naïve patients: results of a combined analysis.
Martin VT; Valade D; Almas M; Hettiarachchi J; Sikes C; Albert KS; Parsons B
Headache; 2007 Feb; 47(2):181-8. PubMed ID: 17300357
[TBL] [Abstract][Full Text] [Related]
15. A global real-world assessment of the impact on health-related quality of life and work productivity of migraine in patients with insufficient versus good response to triptan medication.
Lombard L; Farrar M; Ye W; Kim Y; Cotton S; Buchanan AS; Jackson J; Joshi S
J Headache Pain; 2020 Apr; 21(1):41. PubMed ID: 32349662
[TBL] [Abstract][Full Text] [Related]
16. Predictors of Triptan Response in Pediatric Migraine.
Johnson HF; Goadsby PJ; Gelfand AA
Pediatr Neurol; 2016 May; 58():37-40. PubMed ID: 26968976
[TBL] [Abstract][Full Text] [Related]
17. A cross-sectional survey to assess the migraineur's medication decision-making beliefs: determining when a migraine is triptan-worthy.
Landy SH; Turner IM; Runken MC; Lee M; Sulcs E; Bell CF
Headache; 2013; 53(7):1134-46. PubMed ID: 23773016
[TBL] [Abstract][Full Text] [Related]
18. Factors associated with triptan use in episodic migraine: results from the American Migraine Prevalence and Prevention Study.
Chu MK; Buse DC; Bigal ME; Serrano D; Lipton RB
Headache; 2012 Feb; 52(2):213-23. PubMed ID: 22413150
[TBL] [Abstract][Full Text] [Related]
19. G protein beta3 polymorphism and triptan response in cluster headache.
Schürks M; Kurth T; Stude P; Rimmbach C; de Jesus J; Jonjic M; Diener HC; Rosskopf D
Clin Pharmacol Ther; 2007 Oct; 82(4):396-401. PubMed ID: 17361120
[TBL] [Abstract][Full Text] [Related]
20. Post Hoc Subanalysis of Two Randomized, Controlled Phase 3 Trials Evaluating Diclofenac Potassium for Oral Solution: Impact of Migraine-Associated Nausea and Prior Triptan Use on Efficacy.
Lipton RB; Schmidt P; Diener HC
Headache; 2017 May; 57(5):756-765. PubMed ID: 28386945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
